Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates

分组1 - Metagenomi Therapeutics reported a quarterly loss of $0.6 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.58, but an improvement from a loss of $0.63 per share a year ago, indicating an earnings surprise of -4.35% [1] - The company generated revenues of $3.91 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 54.84%, and down from $9.61 million in the same quarter last year [2] - Over the last four quarters, Metagenomi has surpassed consensus EPS estimates two times and topped revenue estimates only once [2] 分组2 - The stock has underperformed the market, losing about 1.2% since the beginning of the year, while the S&P 500 has gained 0.4% [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at -$0.50 on revenues of $8.66 million for the coming quarter, and -$1.71 on revenues of $25.42 million for the current fiscal year [7] - The Medical - Generic Drugs industry, to which Metagenomi belongs, is currently ranked in the bottom 34% of over 250 Zacks industries, indicating potential challenges for stock performance [8]